$TPTX News
Last published 2y ago
- 2y agoAUPHAPLSCMPITPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
- 2y agoAKROAPLSAUPHHRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
- 3y agoBMYILMNTPTXGlobal Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading RoleGlobeNewswireNew York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences.
- 4y agoBMYTPTXBristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point TherapeuticsBusiness WireBristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the rec
- 4y agoTPTXTurning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational UpdatesGlobeNewswirePositive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib i
- 4y agoTPTXTurning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLCGlobeNewswireSAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedbac
- 4y agoBMYIMTXTPTXBristol Myers Squibb Reports Second Quarter Financial Results for 2022Business WireReports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non
- 4y agoBMYTPTXBristol Myers Squibb Announces Extension of Turning Point Tender OfferBusiness WireBristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. ("Offeror"), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the "Offer") to acquire (the "Acquisition") all of the outstan
- 4y agoTPTXTurning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer TherapiesGlobeNewswireHOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD
- 4y agoPDOKTAJOANAAL+5Stocks making the biggest moves midday: Coinbase, Tesla, American Airlines and moreCNBCCheck out the stocks making headlines on Wall Street on Friday, June 3.
- 4y agoTSLACRWDRHLULU+8Stocks making the biggest moves premarket: Turning Point Therapeutics, Lululemon, RH and othersCNBCThese are the stocks posting the largest moves before the bell.
- 4y agoBMYTPTXBristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology CompanyBusiness WireAcquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023 Bristol Myers
- 4y agoTPTXTurning Point Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athen
- 4y agoTPTXTurning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial OfficerGlobeNewswireSAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sab
- 4y agoTPTXTurning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational UpdatesGlobeNewswireGranted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have not Received Prior Platinum-Based Chemotherapy Repo
- 4y agoTPTXTurning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior ChemotherapyGlobeNewswireSAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Admin
- 4y agoTPTXTurning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova MedicinesGlobeNewswireStrategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 202
- 4y agoTPTXZLABZai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 StudyGlobeNewswire91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+
- 4y agoTPTXZLABTurning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 StudyGlobeNewswire91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+
- 4y agoATRSCLVSGSKONCY+2Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases IncreasingPR NewswirePALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab.
- 4y agoTPTXTurning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 StudyGlobeNewswireIn a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88) In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85%
- 4y agoTPTXTurning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General CounselGlobeNewswireSAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Bri
- 4y agoTPTXTurning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient PopulationGlobeNewswireEnrollment target achieved for expansion cohort 6 (EXP-6) for repotrectinib in NTRK-positive TKI-pretreated advanced solid tumors Company anticipates second repotrectinib pre-NDA meeting in first quarter 2023 to discuss registration timeline for NTRK
- 4y agoBAXCFXMWASYNH+1Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology CompanyGlobeNewswireWilmington DE,, March 11, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced the future composition of the Board of Directors (the "Board") of the Company, which will be renamed Enovis Corp
- 4y agoTPTXTurning Point Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following in
- 4y agoTPTXTurning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - UpdateGlobeNewswireSAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that due to a conference schedule cha
- 4y agoTPTXTurning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare ConferenceGlobeNewswireSAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countou
- 4y agoTPTXTurning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational UpdatesGlobeNewswireOn Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022 Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation in China Other Clinical and Preclinical Programs Continue
- 4y agoTPTXTurning Point Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countour
- 4y agoTPTXTurning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung CancerGlobeNewswireSAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearanc
- 4y agoTPTXTurning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline MilestonesGlobeNewswireStrong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated NSCLC cohort TRIDENT-1 topline BICR ORR and DOR data from ROS1+ NSCLC cohorts
- 4y agoCTSSYNHTPTXSyneos Health Appoints Two New Independent DirectorsGlobeNewswireMORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulu
- 4y agoTPTXTurning Point Therapeutics Provides Regulatory UpdatesGlobeNewswireSAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced regulatory updates for its lead drug c
- 5y agoTPTXTurning Point Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countour
- 5y agoTPTXTurning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational UpdatesGlobeNewswireUpdated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC Conference Multiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and Elzovantinib Cash, Cash Equivalents,
- 5y agoTPTXTurning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor RelationsGlobeNewswireSAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., M
- 5y agoTPTXTurning Point Therapeutics to Host Third Quarter 2021 Conference CallGlobeNewswireSAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will report third quarter fina
- 5y agoTPTXTurning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual CongressGlobeNewswireEarly Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses in 3 of 4 TKI-Naïve Patients SAN DIEGO, Oct.
- 5y agoTPTXTurning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung CancerGlobeNewswireSAN DIEGO, Calif. and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of p
- 5y agoTPTXTurning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual CongressGlobeNewswireSAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical da
- 5y agoTPTXTurning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC ConferenceGlobeNewswireConfirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations Breakthrough
- 5y agoTPTXTurning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory UpdatesGlobeNewswireRepotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 Study Repotrectinib Demonstrates Confirmed Objective Response Rate of 53 Percent in R
- 5y agoTPTXZLABZai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid TumorsGlobeNewswireSHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) partner Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genet
- 5y agoTPTXTurning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid TumorsGlobeNewswireSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration
- 5y agoTPTXTurning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC ConferenceGlobeNewswireSAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced additional details for its data prese
- 5y agoTPTXTurning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC ConferenceGlobeNewswireSAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker abstract of early clin
- 5y agoTPTXTurning Point Therapeutics to Participate In Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countou
- 5y agoTPTXTurning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid TumorsGlobeNewswireSAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of the first cohort of its
- 5y agoTPTXTurning Point Therapeutics Granted Sixth Regulatory Designation for RepotrectinibGlobeNewswireSAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration
- 5y agoTPTXTurning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational UpdatesGlobeNewswirePhase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1) TPX-0022 Granted Fast Track Designation in MET Amplified Advanced or Metastatic Gastric Cancer or Gastroesoph